XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Asset and Liability
The following table summarizes the values of contract assets, capitalized commissions, and contract liabilities for Pharma Services as of December 31, 2021 and 2020 (in thousands):
20212020
Current pharma contract assets(1)
$1,738 $1,643 
Long-term pharma contract assets(2)
236 290 
Total pharma contract assets$1,974 $1,933 
Current pharma capitalized commissions(1)
$109 $185 
Long-term pharma capitalized commissions(2)
882 970 
Total pharma capitalized commissions$991 $1,155 
Current pharma contract liabilities$5,192 $4,029 
Long-term pharma contract liabilities(3)
917 712 
Total pharma contract liabilities$6,109 $4,741 
(1) Recorded within other current assets on the Consolidated Balance Sheets.
(2) Recorded within other assets on the Consolidated Balance Sheets.
(3) Recorded within other long-term liabilities on the Consolidated Balance Sheets.
Disaggregation of Revenue
The following table details the disaggregation of net revenue for both the Clinical Services and Pharma Services Segments for the years ended December 31, 2021, 2020, and 2019 (in thousands):
202120202019
Clinical Services:
    Client direct billing$252,617 $240,535 $212,703 
    Commercial insurance78,773 76,550 83,107 
    Medicare and other government72,010 64,776 64,745 
    Self-pay772 476 606 
Total Clinical Services404,172 382,337 361,161 
Pharma Services80,157 62,111 47,669 
Total net revenue$484,329 $444,448 $408,830